Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zalicus has initiated Phase 1 trial evaluating the pharmacokinetics and safety of Z944, an oral T-type calcium channel blocker for the treatment of acute and inflammatory pain.
Subscribe to our email newsletter
Zalicus has drawn the remaining $8.5m from its $20m secured credit facility with Oxford Finance to fund ion channel clinical development.
Zalicus CEO Mark Corrigan said they look forward to report data from these Phase 1 studies in 2012.
"Z944 is the second study emanating from our ion channel discovery platform this month, following closely on the heels of Z160, an N-type calcium channel blocker," Corrigan added.